{
  "issues": [
    "Agent 2 selects a contrast‑enhanced CT Pulmonary Angiography (CTPA) despite critical hyperkalemia (K⁺ = 5.8 mmol/L) and severe hypotension (MAP = 57 mmHg), which significantly increase the risk of contrast‑induced nephropathy and hemodynamic decompensation.",
    "Renal tool flags missing BMI and lab timestamps; these missing data could affect contrast dosing calculations and risk stratification.",
    "Protocol description includes an unclear “contrast‑to‑eGFR ratio <1.1 g/(mL/min)” metric that is not referenced in KDIGO or ACR guidelines.",
    "Agent 2 does not mention alternative non‑contrast imaging modalities such as a ventilation/perfusion (V/Q) scan, which is often preferred in patients with severe CKD and hemodynamic instability.",
    "No explicit pre‑hydration, post‑hydration, or electrolyte management plan is provided to mitigate the risk of further renal injury and hyperkalemia after contrast administration.",
    "The low‑dose non‑contrast CT protocol listed is for lung cancer screening, not for acute evaluation of PE; it would not address the clinical question."
  ],
  "recommendations": [
    "Re‑evaluate the need for CTPA; if clinical suspicion for PE is moderate, consider a V/Q scan or bedside transthoracic echocardiography as first‑line alternatives that avoid iodinated contrast.",
    "If CTPA is deemed essential, implement aggressive renal protection: isotonic IV saline (unless contraindicated by heart failure), use iso‑osmolar, low‑iodine‑concentration contrast, and reduce volume to the minimum required (e.g., 70 mL for a 70‑kg patient).",
    "Correct hyperkalemia before contrast administration (e.g., IV insulin‑glucose, calcium gluconate, or potassium‑binding agents) and monitor cardiac rhythm continuously.",
    "Document patient’s BMI to allow accurate weight‑based contrast dosing; if BMI is unavailable, use an estimated weight based on height and age.",
    "Obtain precise timestamps for all relevant labs (creatinine, BUN, potassium) within 24 h of the scan to ensure up‑to‑date risk assessment.",
    "Amend the protocol notes to reference KDIGO and ACR guidelines for contrast use in eGFR < 30 mL/min/1.73 m², removing the non‑standard contrast‑to‑eGFR ratio metric.",
    "Include post‑scan monitoring: repeat serum creatinine and potassium at 24–48 h, and consider nephrology consult for ongoing renal management."
  ],
  "confidence": 0.78,
  "agent2_confidence": 0.45,
  "timestamp": "2025-09-08T05:34:26.792416Z",
  "tool_outputs": {
    "renal": {
      "tool_id": "renal_tool_v2",
      "checks": [
        {
          "id": "egfr_ckd_epi",
          "units": "ml/min/1.73m2",
          "timestamp": "2025-09-08T05:34:23.584268Z",
          "priority": "critical",
          "value": 22.0,
          "status": "fail",
          "reason": "High renal risk; contrast caution."
        },
        {
          "id": "creatinine_mg_dl",
          "units": "mg/dL",
          "timestamp": "2025-09-08T05:34:23.584276Z",
          "priority": "critical",
          "value": 3.2,
          "status": "fail",
          "reason": "Creatinine significantly elevated."
        },
        {
          "id": "bun_creatinine_ratio",
          "timestamp": "2025-09-08T05:34:23.584280Z",
          "priority": "important",
          "value": 20.3,
          "status": "warning",
          "reason": "BUN/Cr ratio suggests prerenal azotemia."
        },
        {
          "id": "potassium_mmol_l",
          "units": "mEq/L",
          "timestamp": "2025-09-08T05:34:23.584287Z",
          "priority": "important",
          "value": 5.8,
          "status": "fail",
          "reason": "Critical hyperkalemia."
        }
      ],
      "summary": {
        "overall": "fail",
        "reasons": [
          "High renal risk; contrast caution.",
          "Creatinine significantly elevated.",
          "BUN/Cr ratio suggests prerenal azotemia.",
          "Critical hyperkalemia.",
          "Missing BMI or creatinine.",
          "No lab timestamps provided."
        ],
        "confidence": 0.52
      },
      "metadata": {
        "version": "2.0.0",
        "run_ts": "2025-09-08T05:34:23.584305Z"
      }
    }
  },
  "llm_raw": "{\n  \"issues\": [\n    \"Agent 2 selects a contrast‑enhanced CT Pulmonary Angiography (CTPA) despite critical hyperkalemia (K⁺ = 5.8 mmol/L) and severe hypotension (MAP = 57 mmHg), which significantly increase the risk of contrast‑induced nephropathy and hemodynamic decompensation.\",\n    \"Renal tool flags missing BMI and lab timestamps; these missing data could affect contrast dosing calculations and risk stratification.\",\n    \"Protocol description includes an unclear “contrast‑to‑eGFR ratio <1.1 g/(mL/min)” metric that is not referenced in KDIGO or ACR guidelines.\",\n    \"Agent 2 does not mention alternative non‑contrast imaging modalities such as a ventilation/perfusion (V/Q) scan, which is often preferred in patients with severe CKD and hemodynamic instability.\",\n    \"No explicit pre‑hydration, post‑hydration, or electrolyte management plan is provided to mitigate the risk of further renal injury and hyperkalemia after contrast administration.\",\n    \"The low‑dose non‑contrast CT protocol listed is for lung cancer screening, not for acute evaluation of PE; it would not address the clinical question.\"\n  ],\n  \"recommendations\": [\n    \"Re‑evaluate the need for CTPA; if clinical suspicion for PE is moderate, consider a V/Q scan or bedside transthoracic echocardiography as first‑line alternatives that avoid iodinated contrast.\",\n    \"If CTPA is deemed essential, implement aggressive renal protection: isotonic IV saline (unless contraindicated by heart failure), use iso‑osmolar, low‑iodine‑concentration contrast, and reduce volume to the minimum required (e.g., 70 mL for a 70‑kg patient).\",\n    \"Correct hyperkalemia before contrast administration (e.g., IV insulin‑glucose, calcium gluconate, or potassium‑binding agents) and monitor cardiac rhythm continuously.\",\n    \"Document patient’s BMI to allow accurate weight‑based contrast dosing; if BMI is unavailable, use an estimated weight based on height and age.\",\n    \"Obtain precise timestamps for all relevant labs (creatinine, BUN, potassium) within 24 h of the scan to ensure up‑to‑date risk assessment.\",\n    \"Amend the protocol notes to reference KDIGO and ACR guidelines for contrast use in eGFR < 30 mL/min/1.73 m², removing the non‑standard contrast‑to‑eGFR ratio metric.\",\n    \"Include post‑scan monitoring: repeat serum creatinine and potassium at 24–48 h, and consider nephrology consult for ongoing renal management.\"\n  ],\n  \"confidence\": 0.78\n}",
  "hallucination_analysis": {
    "statement_assessments": [
      {
        "text": "Agent 2 selects a contrast‑enhanced CT Pulmonary Angiography (CTPA) despite critical hyperkalemia (K⁺ = 5.8 mmol/L) and severe hypotension (MAP = 57 mmHg), which significantly increase the risk of contrast‑induced nephropathy and hemodynamic decompensation.",
        "type": "issue",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Renal tool flags missing BMI and lab timestamps; these missing data could affect contrast dosing calculations and risk stratification.",
        "type": "issue",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Protocol description includes an unclear “contrast‑to‑eGFR ratio <1.1 g/(mL/min)” metric that is not referenced in KDIGO or ACR guidelines.",
        "type": "issue",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Agent 2 does not mention alternative non‑contrast imaging modalities such as a ventilation/perfusion (V/Q) scan, which is often preferred in patients with severe CKD and hemodynamic instability.",
        "type": "issue",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "No explicit pre‑hydration, post‑hydration, or electrolyte management plan is provided to mitigate the risk of further renal injury and hyperkalemia after contrast administration.",
        "type": "issue",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "The low‑dose non‑contrast CT protocol listed is for lung cancer screening, not for acute evaluation of PE; it would not address the clinical question.",
        "type": "issue",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Re‑evaluate the need for CTPA; if clinical suspicion for PE is moderate, consider a V/Q scan or bedside transthoracic echocardiography as first‑line alternatives that avoid iodinated contrast.",
        "type": "recommendation",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "If CTPA is deemed essential, implement aggressive renal protection: isotonic IV saline (unless contraindicated by heart failure), use iso‑osmolar, low‑iodine‑concentration contrast, and reduce volume to the minimum required (e.g., 70 mL for a 70‑kg patient).",
        "type": "recommendation",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Correct hyperkalemia before contrast administration (e.g., IV insulin‑glucose, calcium gluconate, or potassium‑binding agents) and monitor cardiac rhythm continuously.",
        "type": "recommendation",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Document patient’s BMI to allow accurate weight‑based contrast dosing; if BMI is unavailable, use an estimated weight based on height and age.",
        "type": "recommendation",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Obtain precise timestamps for all relevant labs (creatinine, BUN, potassium) within 24 h of the scan to ensure up‑to‑date risk assessment.",
        "type": "recommendation",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Amend the protocol notes to reference KDIGO and ACR guidelines for contrast use in eGFR < 30 mL/min/1.73 m², removing the non‑standard contrast‑to‑eGFR ratio metric.",
        "type": "recommendation",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      },
      {
        "text": "Include post‑scan monitoring: repeat serum creatinine and potassium at 24–48 h, and consider nephrology consult for ongoing renal management.",
        "type": "recommendation",
        "classification": "supported",
        "rationale": "matches known fact 'f'"
      }
    ],
    "counts": {
      "supported": 13,
      "inferred": 0,
      "domain_safe": 0,
      "unverified": 0,
      "contradicted": 0
    },
    "hallucination_score": 0.0,
    "recommendation": {
      "force_revision": false,
      "confidence_reduction": 0.0
    },
    "knowledge_base_summary": {
      "numbers": {
        "subject_id": 30045678.0,
        "hadm_id": 45678912.0,
        "stay_id": 55661234.0,
        "age": 72.0,
        "hospital_expire_flag": 0.0,
        "los_hospital_days": 5.1,
        "los_icu_days": 4.6,
        "creatinine_mg_dl": 3.2,
        "bun_mg_dl": 65.0,
        "glucose_mg_dl": 180.0,
        "hemoglobin_g_dl": 9.5,
        "hematocrit_pct": 28.2,
        "platelet_count": 198.0,
        "wbc_count": 14.7,
        "sodium_meq_l": 134.0,
        "potassium_mmol_l": 5.8,
        "chloride_meq_l": 102.0,
        "bicarbonate_meq_l": 18.0,
        "egfr_ckd_epi": 22.0,
        "ckd_stage": 4.0,
        "bun_creatinine_ratio": 20.3,
        "heart_rate_bpm": 102.0,
        "systolic_bp_mmhg": 86.0,
        "diastolic_bp_mmhg": 42.0,
        "map_mmhg": 57.0,
        "pulse_pressure_mmhg": 44.0,
        "temperature_f": 100.2,
        "spo2_pct": 92.0,
        "respiratory_rate": 26.0,
        "data_completeness_pct": 0.91
      },
      "raw_strings_sample": [
        "18.0",
        "100.2",
        "86",
        "57.0",
        "102.0",
        "55661234",
        "3.2",
        "30045678",
        "20.3",
        "72"
      ]
    }
  },
  "feedback": {
    "issues": [
      "Agent 2 selects a contrast‑enhanced CT Pulmonary Angiography (CTPA) despite critical hyperkalemia (K⁺ = 5.8 mmol/L) and severe hypotension (MAP = 57 mmHg), which significantly increase the risk of contrast‑induced nephropathy and hemodynamic decompensation.",
      "Renal tool flags missing BMI and lab timestamps; these missing data could affect contrast dosing calculations and risk stratification.",
      "Protocol description includes an unclear “contrast‑to‑eGFR ratio <1.1 g/(mL/min)” metric that is not referenced in KDIGO or ACR guidelines.",
      "Agent 2 does not mention alternative non‑contrast imaging modalities such as a ventilation/perfusion (V/Q) scan, which is often preferred in patients with severe CKD and hemodynamic instability.",
      "No explicit pre‑hydration, post‑hydration, or electrolyte management plan is provided to mitigate the risk of further renal injury and hyperkalemia after contrast administration.",
      "The low‑dose non‑contrast CT protocol listed is for lung cancer screening, not for acute evaluation of PE; it would not address the clinical question."
    ],
    "recommendations": [
      "Re‑evaluate the need for CTPA; if clinical suspicion for PE is moderate, consider a V/Q scan or bedside transthoracic echocardiography as first‑line alternatives that avoid iodinated contrast.",
      "If CTPA is deemed essential, implement aggressive renal protection: isotonic IV saline (unless contraindicated by heart failure), use iso‑osmolar, low‑iodine‑concentration contrast, and reduce volume to the minimum required (e.g., 70 mL for a 70‑kg patient).",
      "Correct hyperkalemia before contrast administration (e.g., IV insulin‑glucose, calcium gluconate, or potassium‑binding agents) and monitor cardiac rhythm continuously.",
      "Document patient’s BMI to allow accurate weight‑based contrast dosing; if BMI is unavailable, use an estimated weight based on height and age.",
      "Obtain precise timestamps for all relevant labs (creatinine, BUN, potassium) within 24 h of the scan to ensure up‑to‑date risk assessment.",
      "Amend the protocol notes to reference KDIGO and ACR guidelines for contrast use in eGFR < 30 mL/min/1.73 m², removing the non‑standard contrast‑to‑eGFR ratio metric.",
      "Include post‑scan monitoring: repeat serum creatinine and potassium at 24–48 h, and consider nephrology consult for ongoing renal management."
    ],
    "confidence": 0.78
  }
}